WST — West Pharmaceutical Services, Inc.

The July 23, 2026 Q2 beat (13.8% revenue growth, 12.7% organic, adjusted EPS $2.37 vs. $2.08 consensus) and full-year guidance raise to $8.85-$9.05 have lifted sentiment. Analyst consensus is Buy with an average target around $405, and institutional 13F disclosures show significant accumulation. As of 2026-08-27, price momentum is neutral rather than hot, but the earnings story is clearly positive.

Revenue inflected from near-flat 2024 (Q4'24 +2.2% YoY) to high-single-digit growth through 2025, then accelerated sharply: Q1'26 +21.0% YoY and Q2'26 +13.8% YoY. GAAP EPS moved from $1.82 in Q2'25 to $2.15 in Q2'26, and Q1'26 EPS jumped to $1.92 from $1.23 a year earlier. Operating margin recovered from an 18.4% trough in Q1'25 to a stable ~20.5-21.0% range in 2026, with gross margin up 200bps YoY to 37.7% in Q2'26. The main blemish is cash flow: operating cash flow fell ~30% YoY in both Q1 and Q2 2026 despite higher net income, so the acceleration in reported earnings is not yet being confirmed by cash conversion.

At $346.09, trailing P/E is 43.98 vs. the 5-year average of 43.09, P/S is 7.32 vs. the 5-year average of 8.40, and forward P/E is roughly 38.6x using the FY2026 adjusted EPS midpoint of $8.95. That is expensive on an absolute basis, but roughly neutral versus WST's own history, not historically cheap. The market is paying up for quality and growth, with no deep-value margin of safety.

The stock has already moved from a 52-week low of $223.83 to a high of $386 and is now $346.09, meaning the earnings recovery and guidance raise are substantially priced in. At ~38.6x forward EPS, the price works if WST keeps delivering 12-15% growth; if it beats again and raises, the stock can work toward the $400 analyst zone. If growth decelerates or cash flow stays weak, the multiple has room to compress toward the mid-30s, which would put fair value closer to $300.

As of 2026-08-27, RSI-14 was 46.74, neutral, and the price was 1.02% below the 20-day SMA and 0.94% below the 50-day SMA but 18.69% above the 200-day SMA. That reads as a pullback/consolidation within a longer-term uptrend, not a breakdown. Entry timing would favor waiting for a reclaim of the 20/50-day SMAs or a lower-volume stabilization, but these moving averages are stale after this date.

• GLP-1 and anti-obesity drug boom: WST's high-value components and delivery devices are structurally tied to this growth.
• Biologics penetration: more injectable and prefilled-syringe adoption increases demand for high-integrity containment systems.
• Defensive healthcare rotation: investors have favored quality med-tech/life-sciences names amid macro uncertainty, supporting the multiple.
• Interest rates and valuation: a 38x+ forward multiple leaves WST sensitive to rising rate or derating pressure.
• Operational/supply chain resilience: a Q2 cybersecurity incident in West Vantage showed that execution and margin risks remain.

• Q3 2026 earnings, expected late October/early November; street projection is $820-$835M revenue and adjusted EPS of $2.14-$2.24, so another beat/raise is the key upside catalyst.
• September investor conferences: Wells Fargo on 9/10 and Morgan Stanley on 9/14 could provide management commentary on HVP demand and guidance.
• Continued GLP-1 and biologics volume strength in Proprietary Products, which grew 16.6% in Q2 2026.
• Normalization of operating cash flow in Q3/Q4, which would resolve the main disconnect in the current story.

• Cash flow has lagged earnings: OCF declined ~30% YoY in both Q1 and Q2 2026, and if that persists it questions earnings quality.
• Rich valuation: ~38.6x forward earnings leaves little room for a guidance haircut or multiple compression.
• Customer/concentration risk: GLP-1 tailwinds are real, but a major customer could renegotiate volumes or shift suppliers.
• Operational execution: cybersecurity incidents, West Vantage contract manufacturing margins, and capacity ramp costs are live risks.
• Regulatory/drug pricing pressure on pharma customers could eventually dampen demand for premium packaging components.

WST is a high-quality, competitively moated medical-supplies business with genuine secular growth tailwinds from GLP-1s, biologics, and high-value containment. The Q2 beat and raise confirm operating momentum, margins are expanding, and the balance sheet is conservative. But at ~39x forward earnings and with two quarters of declining operating cash flow, the risk/reward is balanced rather than compelling; this is a hold/accumulate-on-weakness, not a chase at $346.

Applied WST's own 5-year average trailing P/E of approximately 43.1x to the FY2026 adjusted EPS estimate of roughly $8.95, yielding ~$386. This is an independent, valuation-history-based estimate and is below the analyst consensus target of ~$405 because it assumes no further multiple expansion.